Entrada Therapeutics, Inc. (TRDA)

NASDAQ: TRDA · IEX Real-Time Price · USD
13.83
-0.52 (-3.62%)
Mar 28, 2024, 1:59 PM EDT - Market open

Company Description

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases.

Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.

The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy.

Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701.

The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017.

Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Entrada Therapeutics, Inc.
Entrada Therapeutics logo
Country United States
Founded 2016
IPO Date Oct 29, 2021
Industry Biotechnology
Sector Healthcare
Employees 159
CEO Dipal Doshi

Contact Details

Address:
One Design Center Place, Suite 17-500
Boston, Massachusetts 02210
United States
Phone 857-305-1825
Website entradatx.com

Stock Details

Ticker Symbol TRDA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $20.00
CIK Code 0001689375
CUSIP Number 29384C108
ISIN Number US29384C1080
Employer ID 81-3983399
SIC Code 2834

Key Executives

Name Position
Dipal Doshi Chief Executive Officer and Director
Nathan J. Dowden President and Chief Operating Officer
Dr. Natarajan Sethuraman Ph.D. Chief Scientific Officer
Kory James Wentworth CPA Chief Financial Officer and Treasurer
Dr. Jared Cohen J.D., Ph.D. General Counsel
Kerry Robert M.S. Senior Vice President of People
Karla MacDonald Chief Corporate Affairs Officer
Kevin Healy Ph.D. Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Mar 13, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 13, 2024 10-K Annual Report
Mar 13, 2024 8-K Current Report
Mar 6, 2024 144 Filing
Mar 6, 2024 144 Filing
Feb 15, 2024 144 Filing
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 3, 2024 8-K Current Report